
Pharmaceutical Technology
Lumos Pharma Announces Abstract Accepted For Oral Presentation At The 13Th Biennial Scientific Meeting Of The Asia Pacific Pediatric Endocrine Society, APPES 2024
By GlobeNewswire

AUSTIN, Texas, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data from its Phase 2 OraGrowtH210 clinical trial has been accepted for presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, or APPES 2024, to be held October 2-5, 2024 in New Delhi, India. This analysis of data from the OraGrowtH210 Trial evaluating oral LUM-201 for Pediatric Growth Hormone Deficiency (PGHD) will be presented on October 3rd by Professor Paul Hofman, MD, Liggins Institute, University of Auckland, Auckland, New Zealand.
Abstract Presentation: Thursday, October 3rd – Oral Session: Growth & Puberty – 2:30PM Local Time
- Abstract entitled, Growth, IGF-1 and IGFBP-3 Responses to the Oral Growth Hormone (GH) Secretagogue, LUM-201, in Paediatric Growth Hormone Deficiency (PGHD) in the OraGrowtH210 Trial (Paul Hofman, MD, et al)
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~$4.7B global GH market from injectable to oral therapy. LUM-201 is currently being evaluated in multiple Phase 2 clinical studies in Pediatric Growth Hormone Deficiency (PGHD) and has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.
Investor & Media Contact:
Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com
Source: Lumos Pharma, Inc.
First published on Thu, Sep 26, 2024
Enjoyed what you've read so far? Great news - there's more to explore!
Stay up to date with the latest news, a vast collection of tech articles including introductory guides, product reviews, trends and more, thought-provoking interviews, hottest AI blogs and entertaining tech memes.
Plus, get access to branded insights such as informative white papers, intriguing case studies, in-depth reports, enlightening videos and exciting events and webinars from industry-leading global brands.
Dive into TechDogs' treasure trove today and Know Your World of technology!
Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.
Trending GlobeNewswire
Zopes Exchange Upgrades Core Trading System For Greater Stability
By GlobeNewswire
ALL4 Mining Sets New Standard In Cloud Mining Profitability With Groundbreaking Package Launch
By GlobeNewswire
Agentuity Unveils The First Agent-Native Cloud
By GlobeNewswire
BAY Miner Launches Free Mobile Cloud Mining App For Bitcoin, Dogecoin, And Litecoin
By GlobeNewswire
Bondexs Native Utility Token $BDXN Secures Listing On Binance Alpha And Futures
By GlobeNewswire
Join Our Newsletter
Get weekly news, engaging articles, and career tips-all free!
By subscribing to our newsletter, you're cool with our terms and conditions and agree to our Privacy Policy.
Join The Discussion